Taiho and Toray end alliance for early-stage overactive bladder therapy
This article was originally published in Scrip
Executive Summary
Taiho Pharmaceutical, a subsidiary of Otsuka in Japan, and Toray Industries have decided to end an alliance for the co-development of a therapy for overactive bladder disorders, apparently in consideration of the increasing competition in the sector.